CRISPR

CRISPR Therapeutics (CRSP) Stock on 7 December 2025: Latest Price, News, Forecasts and Gene‑Editing Outlook

CRISPR Therapeutics AG (NASDAQ: CRSP) is finishing 2025 in classic high‑beta biotech fashion: big science, big headlines, and big disagreement about where the stock goes next. As of the last U.S. trading session on Friday, 5 December 2025, CRSP changed

7 December 2025

CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

Updated: December 4, 2025 Key takeaways CRISPR Therapeutics stock today: price, volatility and positioning As of pre‑market trading on December 4, 2025, CRISPR Therapeutics AG (NASDAQ: CRSP) is changing hands at roughly $56, just above Wednesday’s close of $55.99, after

4 December 2025

Biotechnology · Investing · Market Analysis · NASDAQ:CRSP · Pharma News · Stocks

Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

What happened today Intellia Therapeutics (NASDAQ: NTLA) is under intense pressure after the company said the patient who experienced Grade 4 liver enzyme and bilirubin elevations in its Phase 3 MAGNITUDE study later died. In a Nov. 6 business update,

7 November 2025

Biotechnology · Clinical Trials · Gene Editing · Health News · NASDAQ:NTLA · Stock Market

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Current News Stock Price and Market Activity CRSP is trading around the mid-$60s ahead of Monday’s open. By Reuters (Nov 2) it was ~$64.04 (up +4.86% on the day) reuters.com. (Nasdaq closes on Oct 31 showed ~$63.99 reuters.com.) Over the

2 November 2025

Biotechnology · CRISPR · Investing · NASDAQ:BEAM · NASDAQ:CRSP · NASDAQ:EDIT · NASDAQ:NTLA · NYSE:AZN · Premarket Analysis · Stock Market

Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

NTLA Stock Plunges on Trial Halt Intellia’s stock implosion began early Monday after the biotech stunned investors with news of a trial pause. Before the market opened on Oct. 27, the Cambridge, MA-based company announced it had temporarily halted patient dosing

28 October 2025

Biotechnology · CRISPR · Investment News · NASDAQ:NTLA · Pharma Industry · Stock Market

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

CRISPR Trial Halt Triggers Sell-Off Intellia’s stock was hammered on Monday after the biotech stunned investors with news of a clinical trial pause. Before the opening bell, the Cambridge, MA-based company announced it had temporarily halted patient dosing and screening

27 October 2025

Biotechnology · CRISPR · Gene Editing · Pharmaceutical Industry · Stock Market

CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?

Stock Price Rollercoaster in 2025 CRISPR Therapeutics’ stock has been on a wild ride this year. As of midday October 27, CRSP hovered around $67 per share – off its highs but still up dramatically from early 2025 levels genengnews.com.

27 October 2025

Biotechnology · CRISPR · Gene Editing · Investment Analysis · NASDAQ:CRSP · NASDAQ:EDIT · NASDAQ:NTLA · Stock Market

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Clinical and Pipeline Progress CRISPR Therapeutics has reported a string of positive R&D updates in recent weeks. On October 10, 2025, CRSP presented preclinical results for CTX460, its SyNTase-based therapy for alpha-1 antitrypsin deficiency (AATD). The data – highlighted at

19 October 2025

Biotechnology · Gene Editing · Healthcare Innovation · Investment Analysis · NASDAQ:CRSP · Stock Market

CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

Stock Price, Volume and Sentiment According to AAII, CRSP’s share price on 8 Oct 2025 closed at $77.727, up 10.06 % from the previous close. The stock traded between $70.77 and $78.38 that day and has risen ~20 % during October. Over the prior

8 October 2025

Biotechnology · Gene Editing · Investment Analysis · Market Trends · NASDAQ:CRSP · Stocks

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia at a Glance: CRISPR Trailblazer in 2025 Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology company at the forefront of CRISPRgene editing medicines. Headquartered in Cambridge, MA, Intellia was one of the first companies to harness CRISPR-Cas9 technology to

8 October 2025

Biotechnology · Gene Editing · Investment Analysis · NASDAQ:NTLA · Pharmaceutical News · Stock Market

Biting Back: How CRISPR-Edited Mice Could Stop the Lyme Disease Plague

Lyme Disease on the Rise – And Why Mice Matter Lyme disease is often called a “plague” on Nantucket. The tiny Massachusetts island, famed for its beaches, has one of the nation’s highest infection rates media.mit.edu. About 15% of Nantucket’s

23 September 2025

Biotechnology · Disease Prevention · Genetics · Public Health · Science News

CRISPR ‘Prime Editing’ Breakthrough Cures Genetic Liver Disease in Mice

Breaking the Genetic “Spell” of a Liver Disease Phenylketonuria (PKU) is a hereditary metabolic liver disorder where a single DNA typo disrupts the PAH enzyme that breaks down phenylalanine, an amino acid nature.com fiercebiotech.com. Without a working PAH enzyme, phenylalanine

15 September 2025

Breakthroughs · CRISPR · Genetics · Health · Medical Research